vTv Therapeutics LLC, a US-based pharmaceutical company, has announced receiving a cancellation notification from China-based Huadong Medicine Co., Ltd (SHE: 000963) regarding their collaboration on the type 2 diabetes drug TTP273. Huadong confirmed the news, stating that TTP273 was considered inferior to its in-house developed drug HDM1002.
TTP273, a first-in-class non-peptide and highly selective glucagon-like peptide-1 receptor (GLP-1R) agonist, was developed by vTv through its TTP Translational Technology small-molecule R&D platform. In December 2017, Huadong entered into a USD 33 million licensing deal with vTv for the exclusive intellectual property and commercialization rights to the drug candidate in 16 countries and regions, including Greater China (mainland, Hong Kong, Macau, and Taiwan), South Korea, and Australia, following the conclusion of TTP273’s Phase IIa clinical trials.
HDM1002, on the other hand, is an oral, selective GLP-1 receptor agonist developed by Huadong that strongly activates the GLP-1 receptor, induces the production of cyclic adenosine monophosphate (cAMP), and has shown strong effects on improving glucose tolerance, lowering blood sugar, and promoting weight loss, with good safety demonstrated in preclinical trials. The drug is currently undergoing a Phase Ib clinical study, with clinical trial applications filed in China and the United States in February and April of the previous year, respectively.- Flcube.com
